ClinicalTrials.gg
CompletedNCT00289978FREEDOMSUpdated Apr 11, 2012Results posted

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

A Phase 3 interventional study of Fingolimod 1.25 mg and Fingolimod 0.5 mg in Relapsing-remitting Multiple Sclerosis, sponsored by Novartis. Completed at 115 sites in 19 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2012-04-11.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,272
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
Largest of 19
1,272 · median 142
Started
2006
with 1 other
Phase 3
5 of 19
none open now
Registered
1st of 19
by date
Lead sponsor
2 of 19
Novartis

Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one has the largest enrollment, is one of 2 that started in 2006, is one of 5 in phase 3, and was the 1st registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)

03

Conditions studied

  • Relapsing-remitting Multiple Sclerosis

Keywords

  • Multiple Sclerosis
  • FTY720
  • Fingolimod
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis
  • Patients with a relapsing-remitting disease course
  • Patients with EDSS score of 0-5.5

Exclusion criteria

Exclusion Criteria:

  • Patients with other chronic disease of the immune system, , acute pulmonary disease, cardiac failure, etc.
  • Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria applied to this study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,272 participants (actual)

Study arms

  • Experimental
    Fingolimod 1.25 mg

    Drug: Fingolimod 1.25 mg

  • Experimental
    Fingolimod 0.5 mg

    Drug: Fingolimod 0.5 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Patients self-administered fingolimod 1.25 mg capsules orally once daily.

  • Patients self-administered fingolimod 0.5 mg capsules orally once daily.

  • DrugPlacebo

    Patients self-administered a fingolimod placebo capsule orally once daily.

06

What researchers measure

Primary outcomes

  1. Estimated Annualized Aggregate Relapse Rate (ARR)

    The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group calculated as the total number of confirmed relapses divided by the total number of days on study, multiplied by 365.25.

    Time frame: Baseline to end of study (Month 24)

Secondary outcomes

  1. Percentage of Patients Free of Disability Progression at Month 24 Assessed With the Expanded Disability Status Scale (EDSS)

    EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the following: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. A 3-month confirmed disability progression required onset EDSS, 3-month confirming EDSS, and all EDSS in between to meet the disability progression criteria. Percent of free of disability progression was calculated using the Kaplan Meier method.

    Time frame: Baseline to end of study (Month 24)

  2. Number of New or Newly Enlarged T2 Lesions at Month 24 in Comparison With Baseline

    The number of new or newly enlarged T2 lesions at Month 24 in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.

    Time frame: Baseline to end of study (Month 24)

07

Results

Posted Mar 16, 2011

Participant flow

Participant flow — Overall Study
MilestoneFingolimod 1.25 mgFingolimod 0.5 mgPlacebo
Started429425418
Completed332369332
Not completed975686
Withdrew: Withdrawal by subject311728
Withdrew: Adverse event221318
Withdrew: Lack of efficacy13625
Withdrew: Abnormal laboratory value(s)2091
Withdrew: Lost to follow-up357
Withdrew: Protocol violation554
Withdrew: Abnormal test procedure result(s)211
Withdrew: Death102

Outcome measures

PrimaryEstimated Annualized Aggregate Relapse Rate (ARR)

The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group calculated as the total number of confirmed relapses divided by the total number of days on study, multiplied by 365.25.

Time frame:
Baseline to end of study (Month 24)
Reported as:
Number · Relapses per year
Estimated Annualized Aggregate Relapse Rate (ARR)
Relapses per yearFingolimod 1.25 mgFingolimod 0.5 mgPlacebo
Estimated Annualized Aggregate Relapse Rate (ARR)0.16 (0.13 to 0.19)0.18 (0.15 to 0.22)0.40 (0.34 to 0.47)
SecondaryPercentage of Patients Free of Disability Progression at Month 24 Assessed With the Expanded Disability Status Scale (EDSS)

EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the following: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. A 3-month confirmed disability progression required onset EDSS, 3-month confirming EDSS, and all EDSS in between to meet the disability progression criteria. Percent of free of disability progression was calculated using the Kaplan Meier method.

Time frame:
Baseline to end of study (Month 24)
Reported as:
Number · Percentage of participants
Percentage of Patients Free of Disability Progression at Month 24 Assessed With the Expanded Disability Status Scale (EDSS)
Percentage of participantsFingolimod 1.25 mgFingolimod 0.5 mgPlacebo
Percentage of Patients Free of Disability Progression at Month 24 Assessed With the Expanded Disability Status Scale (EDSS)83.4 ± 1.8782.3 ± 1.8975.9 ± 2.17
SecondaryNumber of New or Newly Enlarged T2 Lesions at Month 24 in Comparison With Baseline

The number of new or newly enlarged T2 lesions at Month 24 in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.

Time frame:
Baseline to end of study (Month 24)
Reported as:
Mean · T2 lesions
Number of New or Newly Enlarged T2 Lesions at Month 24 in Comparison With Baseline
T2 lesionsFingolimod 1.25 mgFingolimod 0.5 mgPlacebo
Number of New or Newly Enlarged T2 Lesions at Month 24 in Comparison With Baseline2.5 ± 5.522.5 ± 7.199.8 ± 13.17

Adverse events

Collected over 24 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod 1.25 mg—51/429 (11.9%)346/429 (80.7%)
Fingolimod 0.5 mg—43/425 (10.1%)355/425 (83.5%)
Placebo—56/418 (13.4%)323/418 (77.3%)
Most frequent serious events
Showing 10 of 155
Most frequent serious events
EventFingolimod 1.25 mgFingolimod 0.5 mgPlacebo
BradycardiaCardiac disorders3/4294/4251/418
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/4294/4252/418
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/4290/4253/418
AbortionPregnancy, puerperium and perinatal conditions0/4290/4253/418
Macular oedemaEye disorders3/4290/4250/418
Multiple sclerosis relapseNervous system disorders3/4292/4251/418
Myocardial infarctionCardiac disorders0/4290/4252/418
Non-cardiac chest painGeneral disorders0/4292/4252/418
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/4290/4252/418
Chest painGeneral disorders0/4292/4250/418
Most frequent other events
Showing 10 of 28
Most frequent other events
EventFingolimod 1.25 mgFingolimod 0.5 mgPlacebo
NasopharyngitisInfections and infestations112/429115/425115/418
HeadacheNervous system disorders113/429107/42596/418
Upper respiratory tract infectionInfections and infestations62/42973/42572/418
InfluenzaInfections and infestations40/42955/42541/418
DiarrhoeaGastrointestinal disorders40/42950/42530/418
Back painMusculoskeletal and connective tissue disorders45/42949/42528/418
Alanine aminotransferase increasedInvestigations49/42942/42516/418
FatigueGeneral disorders46/42948/42545/418
Urinary tract infectionInfections and infestations21/42934/42547/418
CoughRespiratory, thoracic and mediastinal disorders37/42943/42534/418

Baseline characteristics

Age Continuous
Age Continuous(years)Fingolimod 1.25 mgFingolimod 0.5 mgPlaceboTotal
Mean37.4 ± 8.9136.6 ± 8.7737.2 ± 8.6037.1 ± 8.76
Age, Customized
Age, Customized(participants)Fingolimod 1.25 mgFingolimod 0.5 mgPlaceboTotal
<18 years1001
18 -3010712097324
31-40147162165474
41-55174143156473
Sex: Female, Male
Sex: Female, Male(Participants)Fingolimod 1.25 mgFingolimod 0.5 mgPlaceboTotal
Female295296298889
Male134129120383
Duration of multiple sclerosis since first symptoms
Duration of multiple sclerosis since first symptoms(Years)Fingolimod 1.25 mgFingolimod 0.5 mgPlaceboTotal
Mean8.4 ± 6.868.0 ± 6.608.1 ± 6.358.2 ± 6.60
Number of relapses in last 2 years
Number of relapses in last 2 years(relapses)Fingolimod 1.25 mgFingolimod 0.5 mgPlaceboTotal
Mean1.5 ± 0.811.5 ± 0.761.4 ± 0.731.5 ± 0.77
Expanded Disability Status Scale (EDSS)
Expanded Disability Status Scale (EDSS)(Units on a scale)Fingolimod 1.25 mgFingolimod 0.5 mgPlaceboTotal
Mean2.41 ± 1.362.30 ± 1.292.49 ± 1.292.40 ± 1.32
08

Study locations

115 sites
  • The Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
  • North Gosford Private Hospital
    Burrabil Avenue, Suite 17, Gosford, NSW 2250, Australia
  • Strategic Health Evaluators
    Chatswood, 2067, Australia
  • St Vincent's Hospital Melbourne, Department of Clinical Neurosciences
    Fitzroy, 3065 VIC, Australia
  • Austin Health, Department of Neurology
    Heidelberg, 3084, Australia
  • Algemeen Ziekenhuis St. Jan, Department of Neurology
    Ruddershove 10, Brugge 8000, Belgium
  • Erasme Hospital
    Route de Lennik 808, Brussels 1070, Belgium
  • CHU Charleroi, Hôpital Civil
    Boulevard Paul Janson 92, Charleroi 6000, Belgium
  • University Hospital Gasthuisberg
    Department Neurology, Herestraat 49, Leuven 3000, Belgium
  • AZ Alma
    Department of Neurology & Rehab-Umit, Gentsesteenweg 132, Sijsele 8340, Belgium
  • Regionaal Ziekenhuis
    St.Trudo, Diestersteenweg 100,, St.Truiden 3800, Belgium
  • MS Klinik
    Boemerangstraat 2, Overpelt, 3900, Belgium
  • National Multiple Sclerose Centrum v.z.w
    Vanheylenstraat 16, Melsbroek, 1820, Belgium
  • University of British Columbia
    ME498 2211 Wesbrook Mall, Vancouver, British Columbia V6T 2B5, Canada
  • DMSRU - Capital Health
    Halifax, Nova Scotia, Canada
  • Kingston General Hospital, MS Clinic
    Connell 7, 76 Stuart Street, Kingston, Ontario K7L 2V7, Canada
  • Nepean Medical Center
    Ottawa, Ontario K2G 6E2, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • Clinical Trials Office,
    Trillium Health Center, 00 Queesway West, Mississauga, Ontario L5B 1B8, Canada
  • Hopital Maisonneuve-Rosemont, Recherche Clinique de Neurologie
    Montreal, Quebec H1T 2M4, Canada
  • University of Saskatchewan
    Regina, Saskatchewan S4T 1A5, Canada
  • Military Hospital of Brno
    Department of Neurology, Zabrdovicka 3, Brno 63600, Czech Republic
  • Faculty Hospital St. Anne
    First Department of Neurology, Pekarska 53, Brno 65691, Czech Republic
  • Faculty Hospital
    Department of Neurology, I.P. Paulova 6, Olomouc 77520, Czech Republic
  • Hospital of Pardubice
    Department of Neurology, Kyjevska 44, Pardubice 53203, Czech Republic
  • Faculty Hospital
    Department of Neurology, Alej Svobody 80, Plzeň 3046, Czech Republic
  • Faculty Hospital Motol, MS Center
    Department of Neurology, V Uvalu 84, Prague 5 15006, Czech Republic
  • Vseobecna fakultni nemocnice
    MS Centrum, Neurologicka klinika, Karlovo namesti 32, Praha 2 12808, Czech Republic
  • Neurologicka klinika, Fakultni nemocnice
    Kralovske Vinohrady, Srobarova 50, Praha 10034, Czech Republic
  • MS Centrum
    Neurology Department of Hospital Teplice, Duchcovska 53, Teplice 41529, Czech Republic
  • Centrum neurologicke pece
    Jiraskova 1389, Rychnov nad Kneznou, 51601, Czech Republic
  • Facultní Nemocnice Spoliklinikou Ostrava, Neurology Department
    Ostrava, 70852, Czech Republic
  • Helsinki Headache Center Postitalon Lääkäriasema
    Mannnerheiminaukio 1 B 2 Floor, Helsinki 0100, Finland
  • Finnish Special Neurology Center Ltd.
    Brahenkatu 11 D,, Turku 20100, Finland
  • Suomen Terveystalo/ Päänsärkykeskus, Tampere
    Hämeenkatu 18, 6th fl., Tampere, 33200, Finland
  • Turku University Hospital, Neurology Department 799
    Kiinanmyllynkatu 11- 14, Turku, 20520, Finland
  • Hyvinkään sairaala
    Neurologian poliklinikka, Sairaalankatu 1, Hyvinkää, 05850, Finland
  • CHU La Timone
    Service Neurologie, Boulevard Jean Moulin, Marsielle Cedex 5, 13385, France
  • Investigational Site
    Berlin, 10117, Germany
  • Investigational Site
    Berlin, 13347, Germany
  • Investigational Site
    Dusseldorf, 40225, Germany
  • Investigational Site
    Giessen, 35385, Germany
  • Investigational Site
    Hamburg, 20099, Germany
  • Investigational Site
    Hamburg, 20246, Germany
  • Investigational Site
    Leipzig, 04103, Germany
  • Investigational Site
    Magdeburg, 39120, Germany
  • Investigational Site
    Munchen, 80331, Germany
  • Investigational Site
    Munchen, 81377, Germany
  • Investigational Site
    Munster, 48149, Germany
  • Investigational Site
    Regensburg, 93053, Germany
  • Investigational Site
    Seesen/Harz, 38723, Germany
  • Investigational Site
    Stuttgart, 70191, Germany
  • Investigational Site
    Tubingen, 72076, Germany
  • Investigational Site
    Wurzburg, 97080, Germany
  • Athens Naval Hospital, Neurology Department
    Athens, 11521, Greece
  • Neurology Department Athens General Hospital, G. Gennimatas
    Mesogeion 154 Ave., Athens, 11527, Greece
  • 1st IKA Papadimitriou Neurology Dept
    Terma Zaimi, Melissia-Athens, 15127, Greece
  • University General Hospital of Thessaloniki "AHEPA", B' University Department of Neurology
    Thessaloniki, 54636, Greece
  • Barzilai Medical Center
    Ashkelon, 78306, Israel
  • Carmel Medical Center
    Haifa, 34362, Israel
  • Sieff Medical Center
    Safed, 13100, Israel
  • Sheba - Medical Center
    Tel Hashomer, Ramat-Gan,, 52621, Israel
  • Kaunas University Hospital Department of Neurology
    Eiveniu 2, Kaunas, LY-50009, Lithuania
  • Academisch Ziekenhuis VU
    De Boelelaan 1118, Amsterdam 1081, Netherlands
  • St. Antonius Ziekenhuis
    Postbus 2500, Nieuwegein 3430 EM, Netherlands
  • Multiple Clerosis Center Nijmegen
    Heiweg 97, Nyimegen 6533, Netherlands
  • Erasmus MC
    Dr. Molewaterplein 40, Rotterdam 3015 GD, Netherlands
  • Sint Elisabeth Ziekenhuis
    Hilvarenbeekse Weg 60, Tilburg 5022, Netherlands
  • Maaslandziekenhuis Sittard
    Walramstraat 23, BK Sittard, 6131, Netherlands
  • Samodzielny Publiczny Szpital Kliniczny
    Klinika Neurologii, Ul. Marii Skłodowskiej-Curie 24 A, Bialystok 15-276, Poland
  • Niezalezny Zespol Opieki Zdrowotnej Kendron
    Ul. Swietego Mikolaja 1/8, Bialystok 15-420, Poland
  • Oddzial Neurologiczny i Leczenia Udarow
    Mozgu, Nowe Ogrody 1/6, Gdańsk 80-803, Poland
  • Katedra i Klinika Neurologii Slaskiej Akademii Medycznej
    ul. Medykow 14, Katowice 40-752, Poland
  • Univ. Med. Sci. Poznan, Katedra i Klinika Neurologii,
    Department of Neurology, ul. Przybyszewskiego 49, Poznan 60-355, Poland
  • CSK MSWiA Hospital
    Department of Neurology, Wołoska 137, Warsaw 02-507, Poland
  • Jadwiga Kruszewska-Ozimska, Instytut Psychiatrii i Neurologii
    II Klinika Neurologii, ul. Sobieskiego 1/9, Warsaw 02-957, Poland
  • Centralny Szpital Kliniczny, Klinika Neurologii
    MSWiAw Warszawie, Woloska 137, Warszawa 00-909, Poland
  • Katedra i Klinika Neurologii Centralny Szpital Kliniczny AM w Warszawie
    ul. Banacha 1A, Warszawa 01-097, Poland
  • Medical University of Lodz
    Lodz, Poland
  • Interregional Clinical Diagnistic Center, Neurology Department
    Kazan, 420111, Russian Federation
  • Central Clinical Hospital of Medical Center of Administration of President of Russian Federation
    Moscow, 121356, Russian Federation
  • Moscow Regional Research Clinical Institue
    Moscow, 129110, Russian Federation
  • GUZ "Central Medical Sanitary Department #122 of Federal Medical-Biological agency", Neurology department
    St-Petersburg, Russian Federation
  • Military Medical Academy, Neurology Department
    St. Petersburg, 194044, Russian Federation
  • II. Neurologická klinika Fakultná nemocnica s poliklinikou Bratislava pracovisko Kramáre
    Limbová 5, Bratislava 833 05, Slovakia
  • Neurologická klinika, Martinská fakultná nemocnica
    Kollárova 2, Martin, 03659, Slovakia
  • I. Neurologická klinika, Fakultná nemocnica s poliklinikou Bratislava pracovisko Staré mesto
    Mickiewiczova 13, Bratislava, 813 69, Slovakia
  • Neurologické oddelenie, Nemocnica s poliklinikou Žilina
    ul.V. Spanyola 43, Žilina, 012 07, Slovakia
  • Umhlanga Hospital
    Umhlanga, KZN 4319, South Africa
  • Division of Neurology, Groote Schuur Hospital
    E 8-74, Groote Schuur Hospital, Observatory Cape Town, 7925, South Africa
  • Private Neurologist (Morningside Medi-Clinic), Suite C, Block C, Rochester Place
    Sandton, 2196, South Africa
  • MS Centrum
    Forskningsenhet, SU/Östra CKÖ plan 0, Gothenburg 41345, Sweden
  • Karolinska University Hospital Huddinge
    Department Of Neurology R54, Stockholm, 14186, Sweden
  • Karolinska University Hospital, Department of Medicine
    Neuroimmunology unit, CMM L8:04, Stockholm, 171 76, Sweden
  • Kantonsspital Basel, Policlinic
    Neurology-Neurosurgical, Petersgraben 4, Basel 4031, Switzerland
  • Centre Hospitalier, Universitaire Vaudois Policlinique de Neurologie
    Rue du Bugnon, Lausanne 1011, Switzerland
  • UniversitätsSpital Zürich, Neurologische Klinik
    Frauenklinikstr. 26, Zurich, 8091, Switzerland
  • Hacettepe Universiti Hospitals
    Department of Neurology, Ankara, Turkey
  • Gazi University
    Medical Faculty Neurology Department, Besevler Ankara 06500, Turkey
  • EGE University
    Medical Faculty Hospital Neurolgy Department, Bornova Izmir 35100, Turkey

Showing the first 100 of 115 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Nowak CP, Mutze T, Konietschke F. Group sequential methods for the Mann-Whitney parameter. Stat Methods Med Res. 2022 Oct;31(10):2004-2020. doi: 10.1177/09622802221107103. Epub 2022 Jun 13. PubMed 35698787 ↗
  • Fox RJ, Chan A, Zhang A, Xiao J, Levison D, Lewin JB, Edwards MR, Marantz JL. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Curr Med Res Opin. 2017 Feb;33(2):175-183. doi: 10.1080/03007995.2016.1248380. Epub 2016 Nov 10. PubMed 27733070 ↗
  • Derfuss T, Bergvall NK, Sfikas N, Tomic DL. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis. Curr Med Res Opin. 2015;31(9):1687-91. doi: 10.1185/03007995.2015.1067191. Epub 2015 Aug 20. PubMed 26121423 ↗
  • Kremenchutzky M, O'Connor P, Hohlfeld R, Zhang-Auberson L, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Kappos L. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord. 2014 May;3(3):341-9. doi: 10.1016/j.msard.2013.10.006. Epub 2013 Nov 5. PubMed 25876471 ↗
  • Chinea Martinez AR, Correale J, Coyle PK, Meng X, Tenenbaum N. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses. Adv Ther. 2014 Oct;31(10):1072-81. doi: 10.1007/s12325-014-0154-4. Epub 2014 Sep 23. PubMed 25245812 ↗
  • Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013 Jul;120(7):1432-9. doi: 10.1016/j.ophtha.2012.12.040. Epub 2013 Mar 24. PubMed 23531349 ↗
  • Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol. 2012 Oct;69(10):1259-69. doi: 10.1001/archneurol.2012.1051. PubMed 22751847 ↗
  • Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Haring DA, Francis G, Kappos L; FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Erratum In: Lancet Neurol. 2012 Aug;11(8):658. PubMed 22494956 ↗
  • Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. PubMed 20089952 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2006
First posted
Feb 10, 2006
Start
Jan 2006
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Mar 16, 2011
Last update
Apr 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00289978
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Feb 10, 2006
Start date
Jan 2006
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Mar 16, 2011
Last update
Apr 11, 2012

Study contacts

Novartis Pharmaceuticals
study chair · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion